The authors have informed the editors of the JBMR that Figure 1B, appearing in [1], was inadvertently reproduced from an earlier work published by the authors (Boonen and Cosman) in the JBMR. The following credit line should have appeared in the caption:
Figure adapted from Black and colleagues,(56) with permission from the American Society for Bone and Mineral Research.
![Changes in bone turnover marker levels following discontinuation of (A) ET (urinary NTx [mean ± standard error change from base line in NTx:creatinineratio; %]),(26) (B) zoledronic acid treatment (serum CTx‐I [geometric mean, ng/mL]),(57) and (C) denosumab treatment (serum CTx‐1 [median ± interquartile range; ng/mL]).(70) In A, ET/HT treatment was discontinued at month 36.*p < 0.05, compared with baseline measure; †p < 0.05, compared with placebo group. Figure adapted from Gallagher and colleagues,(26) with permission from The Endocrine Society. In B, the gray, horizontal, long dashed lines indicate premenopausal reference ranges, the arrows indicate timing of infusions, and the vertical dash line indicates the end of the HORIZON‐PFT and the start of the extension study; the year 4.5 measurement was made 6 months after the most recent infusion where as the year 6 measurement was 12 months after the most recent infusion. Results represent geometric means. Z3P3 refers to the group of patients who received zoledronic acid in the HORIZON‐PFT but placebo in the extension study; Z6 refers to the group of patients receiving zoledronic acid in both the HORIZON‐PFT and the extension study. Figure adapted from Black and colleagues,(56) with permission from the American Society for Bone and Mineral Research. In C, the group receiving 30 mg denosumab every 3 months (30 mg Q3M) discontinued denosumab treatmentat month 24 and then recommenced treatmentat month 36 at a dose rate of 60 mg denosumab every 6 months; the groups receiving 210 mg denosumabe very 6 months (210 mg Q6M) or alendronate discontinued treatment at month 24; the dashed line at month 24 indicates the time at which dosing was reallocated. Figure reprinted from Miller and colleagues,(70) with permission from Elsevier. CTx‐I = C‐telopeptide of type I collagen; ET = estrogentherapy; HT = hormonetherapy; NTx = N‐telopeptide of type I collagen; NTx:CR = NTx:creatinineratio.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jbmr/27/11/10.1002_jbmr.1745/1/m_jbmr1745_nfig001.jpeg?Expires=1750342253&Signature=YJri4fxOwscpQIQrnpdffWoFYcisxFzl4sazfV2BSA6W8g~KVlhQxtjBeRneZu7VB~IUamWPn1M39SOfOlW~6x9Y3VTZxGbvXYtI95VuSYt4X2g1KKeUBeRoUL7~UaAe0wWN5cCIN8vUoFFObYQuGDIRIpq4wYC2EQw2z39ljSojeGCZpE25ZyDXhLaz-Z0Z1KzgdxbrsOoDRIY4VXm2tKigLf8piBx-lDfjtCC4H3McGRn5DBQPVIXXUJmQSqQSYbmHDI8MGd5wAZWRFgv3IAGfQwaUoO4oulYQpmLj5aqV46lBqJIG521ByMBcdXvguwQV8GbXmfqAIo7x1U4k1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Changes in bone turnover marker levels following discontinuation of (A) ET (urinary NTx [mean ± standard error change from base line in NTx:creatinineratio; %]),(26) (B) zoledronic acid treatment (serum CTx‐I [geometric mean, ng/mL]),(57) and (C) denosumab treatment (serum CTx‐1 [median ± interquartile range; ng/mL]).(70) In A, ET/HT treatment was discontinued at month 36.*p < 0.05, compared with baseline measure; †p < 0.05, compared with placebo group. Figure adapted from Gallagher and colleagues,(26) with permission from The Endocrine Society. In B, the gray, horizontal, long dashed lines indicate premenopausal reference ranges, the arrows indicate timing of infusions, and the vertical dash line indicates the end of the HORIZON‐PFT and the start of the extension study; the year 4.5 measurement was made 6 months after the most recent infusion where as the year 6 measurement was 12 months after the most recent infusion. Results represent geometric means. Z3P3 refers to the group of patients who received zoledronic acid in the HORIZON‐PFT but placebo in the extension study; Z6 refers to the group of patients receiving zoledronic acid in both the HORIZON‐PFT and the extension study. Figure adapted from Black and colleagues,(56) with permission from the American Society for Bone and Mineral Research. In C, the group receiving 30 mg denosumab every 3 months (30 mg Q3M) discontinued denosumab treatmentat month 24 and then recommenced treatmentat month 36 at a dose rate of 60 mg denosumab every 6 months; the groups receiving 210 mg denosumabe very 6 months (210 mg Q6M) or alendronate discontinued treatment at month 24; the dashed line at month 24 indicates the time at which dosing was reallocated. Figure reprinted from Miller and colleagues,(70) with permission from Elsevier. CTx‐I = C‐telopeptide of type I collagen; ET = estrogentherapy; HT = hormonetherapy; NTx = N‐telopeptide of type I collagen; NTx:CR = NTx:creatinineratio.
The authors also wish to amend errors that appeared in Figure 1B: (1) The x‐axis label should be “Time, Years” instead of “Time, Months”; (2) the data label for Z3P3 should be 0.18 ng/mL instead of –0.18%; (3) the data label for Z6 should be 0.16 ng/mL instead of 0.16%; and (4) the time of infusion arrows should appear slightly to the right of Years 3, 4, and 5 and not directly at Years 3, 4, and 5.The corrected Figure 1 is shown on the following page.
[Insert corrected figure and caption. Caption appears on p. 2.]
The authors regret the error.
